FENG Shu-Qi, JIN Guo-Rong, XUE Qun-Hang, HE Min, WANG Ze-Hang, YAO Jia-Xin, CHEN Long, WANG Yu-Jiao, ZHANG An-Xiu, HE Sheng, ZHOU Bing-Rui, XIE Jun
Diabetic nephropathy (DN) is a serious complication of diabetes mellitus and a leading cause of end-stage renal diseases. In DN patients, key pathological mechanisms include proteinuria, glomerulosclerosis, and fibrosis, largely driven by poor glycemic control and oxidative stress caused by prolonged hyperglycemia. This stress damages renal podocytes and triggers inflammatory mesenchymal infiltration of renal tubular cells, exacerbating the progression of proteinuria and fibrosis. Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) offer promising potential for treating DN due to their strong anti-oxidative properties. In this study, we developed a DN mouse model and treated the mouse via tail vein injections of hUC-MSCs (1×106 cells/mouse). The results indicated that hUC-MSCs significantly lowered fasting blood glucose levels (22.5 ± 3.0 vs 14.7 ± 1.1, P < 0.01) and improved glucose tolerance, as shown by intraperitoneal glucose tolerance test (IPGTT) results (P < 0.05). Additionally, the renal function improved in hUC-MSCs-treated mice, with marked reductions in oxidative stress markers, including blood urea nitrogen (BUN), urinary creatinine (Ucr), urinary protein (PRO), superoxide dismutase (SOD), and malondialdehyde (MDA) (P < 0.05). Histological analyses through hematoxylin-eosin (H&E), Periodic Acid-Schiff (PAS), and Sirius red staining demonstrated alleviation of glomerular mesangial hyperplasia, glomerular hypertrophy, and tubular inflammation. Furthermore, hUC-MSCs treatment downregulated the expression of oxidative stress-related proteins, such as NADPH oxidase 4 (NOX4) and thioredoxin-interacting protein (TXNIP), and reduced reactive oxygen species (ROS) production (P < 0.05). Meanwhile, human renal cortical proximal tubule epithelial cells (HK-2 cells) were selected for validation in vitro experiments using high glucose treatment followed by supernatants of hUC-MSCs (MSC-CM), and Western blotting showed that the expression of both NOX4 and TXNIP was inhibited (P < 0.05) and ROS expression was reduced. In conclusion, hUC-MSC treatment effectively lowered blood glucose levels and improved renal function in DN mice, likely through the suppression of NOX4 expression and TXNIP-mediated oxidative stress.